The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy

Journal of Gene Medicine

Volumn 8, Issue 8, 2006, Pages 1056-1067

  Hayashi, Kyoko ^a   Lee, Jung Bum ^a   Maitani, Yoshie ^b   Toyooka, Naoki ^a   Nemoto, Hideo ^a   Hayashi, Toshimitsu ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Acyclovir; Cancer gene therapy; Diterpenoid; Ganciclovir; HSV thymidine kinase

Indexed keywords

ACICLOVIR; DITERPENOID; GANCICLOVIR; SCOPADULCIOL; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BYSTANDER EFFECT; CANCER CELL; CANCER THERAPY; CELL KILLING; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENETIC TRANSFECTION; HELA CELL; HERPES SIMPLEX VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOSPHORYLATION; PLASMID; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CARCINOMA; CELL LINE, TUMOR; DITERPENES, ABIETANE; FEMALE; GANCICLOVIR; GENE THERAPY; GENES, NEOPLASM; GLIOBLASTOMA; HELA CELLS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, NUDE; MOLECULAR STRUCTURE; PLASMIDS; PRODRUGS; THYMIDINE KINASE; TRANSFECTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS; SIMPLEXVIRUS;

EID: 33747854225     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.931     Document Type: Article

References (58)

1. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovius infection. Drugs 1990; 39: 5997-6331.
2. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci U S A 1977; 74: 5716-5720.
3. Fyfe JA, Keller PM, Furman PA, et al. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2-hydroxyethoxymethyl) guanine. J Biol Chem 1978; 253: 8721-8727.
4. Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 1982; 3: 7-13.
5. Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanine) monophosphate by GMP kinase. J Biol Chem 1980; 255: 7204-7207.
6. Miller WH, Miller RL. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 1982; 31: 3879-3884.
7. Ashton WT, Karkas JD, Field AK, et al. Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′-NDG). Biochem Biophys Res Commun 1982; 108: 1716-1721.
8. Cheng YC, Huang ES, Lin JC, et al. Unique spectrum of activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against herpes viruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci U S A 1983; 80: 2767-2770.
9. Cheng YC, Grill SP, Dutschman GE, et al. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new antiherpes virus compound, in herpes simplex virus-infected cells. J Biol Chem 1983; 258: 12460-12464.
10. Field AK, Davies ME, Dewitt C, et al. 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]lmethylguanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A 1983; 80: 4139-4143.
11. Smee DF, Boehme R, Chernow M, et al. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol 1985; 34: 1049-1056.
12. Furman PA, St. Clair MH, Fyfe JA, et al. Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxymethyl)guanine and its triphosphate. J Virol 1979; 32: 72-77.
13. Culver KW, Ram Z, Walbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
14. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90: 7024-7028.
15. Oldfield H, Ram Z, Culver KW, et al. Gene therapy for the treatment of brain tumors using intratumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39-69.
16. Ram Z, Culver WK, Walbridge S, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
17. Chen SH, Shine HD, Goodman JC, et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994; 91: 3054-3057.
18. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase 1 clinical trial in malignant mesothelioma. Hum. Gene Ther 1998; 9: 1083-1092.
19. Clayman GL, Frank DK, Bruso PA, et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999; 5: 1715-1722.
20. Herman JR, Adler HL, Aguil-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999; 10: 1239-1249.
21. Stewart AK, Lassam NJ, Quirt IC, et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase I clinical trial. Gene Ther 1999; 6: 350-363.
22. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91: 763-771.
23. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
24. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
25. Ezzeddine ZD, Martuza RL, Platikai D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608-614.
26. Freeman SM, Abboud CN, Whartenby KA, et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
27. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997; 33: 1005-1016.
28. +-ATPase from Scoparia dulcis, and its structure-activity relationships. J Natl Prod 1991; 54: 802-809.
29. Hayshi K, Hayashi T. Scopadulciol is an inhibitor of herpes simplex virus type 1 and a potentiator of acyclovir. Antiviral Chem Chemother 1996; 7: 79-85.
30. Balzarini J, Bohman C, DeClercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl) -2′-deoxyuridine,9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993; 268: 6332-6337.
31. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354-1361.
32. Hayashi T, Kishi M, Kawasaki M, et al. Scopadulcic acid-A and -B, new diterpenoids with a novel skeleton, from a Paraguayan crude drug Typychá Kuratû (Scoparia dulcis L.). Tetrahedron Lett 1987; 28: 3693-3696.
33. Yoshikawa M, Kato T, Takenishi T. A novel method for phosphorylation of nucleosides to 5′-nucleotides. Tetrahedron Lett 1967; 50: 5065-5068.
34. Hayashi K, Hayashi T, Sun HD, et al. Potentiation of ganciclovir toxicity in the herpes simplex virus thymidine kinase/ganciclovir administration system by ponicidin. Cancer Gene Ther 2000; 7: 45-52.
35. Jamieson AT, Gentry GA, Subak-Sharpe JH. Induction of both thymidine and deoxythymidine kinase activity in herpes simplex virus. J Gen Virol 1974; 24: 465-480.
36. Taylor JL, Tom P, Guy J, et al. Regulation of herpes simplex virus thymidine kinase in cells treated with a synergistic antiviral combination of α interferon and acyclovir. Antimicrob Agents Chemother 1994; 38: 853-856.
37. Germershausen J, Bostedor R, Field AK, et al. A comparison of the antiviral agents 2′-nor-2′-deoxyguanosine and acyclovir: uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphates. Biochem Biophys Res Commun 1983; 116: 360-367.
38. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637-4642.
39. Hostetler KY, Parker S, Sridhar CN, et al. Acyclovir diphosphate dimyristoylglycerol: A phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus. Proc Natl Acad Si USA 1993; 90: 11835-11839.
40. Smee DF, Martin JC, Verherden JPH, et al. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother 1983; 23: 676-682.
41. Gilula NB, Reeves OR, Steinbach A. Metabolic coupling, ionic coupling and cell contacts. Nature 1972; 235: 262-265.
42. Bi WL, Parysek LM, Wamick R, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
43. Fick J, Barker FGI, Dazin P, et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci U S A 1995; 92: 11071-11075.
44. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ ganciclovir system in vitro. Gene Ther 1996; 3: 85-92.
45. Mesnil M, Piccoli C, Tiraby G, et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 1996; 93: 1831-1835.
46. Mesnil M, Krutovskikh V, Piccoli C, et al. Negative growth control of HeLa cells by connexin gene: connexin species specificity. Cancer Res 1995; 55: 629-639.
47. Namba H, Iwadate Y, Kawamura K, et al. Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin 43 in the target cells. Cancer Gene Ther 2001; 8: 414-420.
48. Mahtha PP, Bertram JS, Leewanstein WR. The actions of retinoids on cellular growth correlate with their actions on gap junctional communication. J Cell Biol 1989; 108: 1053-1065.
49. Park JY, Elshami AA, Amine K, et al. Retinoids augment the bystander effect in vitro and in vivo herpes simplex virus thymidine kinase/ ganciclovir-mediated gene therapy. Gene Ther 1997; 4: 909-917.
50. Watanabe J, Nomata K, Noguchi M, et al. All-trans retinoic acid enhances gap junctional intercellular communication among renal epithelial cells in vitro treated with renal carcinogens. Eur J Cancer 1999; 35: 1003-1008.
51. McMasters RA, Wilbert TN, Jones KE, et al. Two-drug combinations that increase apoptosis and modulate bak and bcl-X(L) expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase. Cancer Gene Ther 2000; 7: 563-573.
52. Hasenburg A, Tong XW, Rojas-Martinez A, et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000; 7: 839-852.
53. Robe PA, Princen F, Martin D, et al. Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ ganciclovir gene therapy system: effects of dibutyril adenosine 3′5′-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside. Biochem Pharmacol 2000; 60: 241-249.
54. Wilder O, Blasese RM, Candotti F. Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res 1999; 59: 5233-5238.
55. Lanuti M, Kouri CE, Force S, et al. Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Ther 1999; 6: 1600-1610.
56. Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytotoxicity by hydroxyurea. Cancer Res 2000; 60: 1631-1636.
57. Boucher PD, Ostruszka LJ, Murphy PJM, et al. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther 2002; 9: 1023-1030.
58. Hayashi T, Okamura K, Kawasaki M, et al. Two chemotypes of Scoparia dulcis in Paraguay. Phytochemisty 1991; 30: 3617-3620.